Omada Health (OMDA) Q4 2025 earnings review
A Milestone Quarter Masking a Structural Illusion
On the surface, Omada Health delivered a blowout quarter: revenue accelerated to 58% YoY growth, GAAP Net Income turned positive for the first time ($5.2M), and Adjusted EBITDA margins expanded to 11.2%. However, a closer look at the data reveals a dangerous reality. Almost all of the company's growth is coming from a single, unnamed 'related party,' which accounted for nearly 70% of total Q4 revenue. Stripped of this related party, core revenue grew a meager 14% YoY and was entirely flat sequentially. Adding to the unease, FY26 guidance projects a sharp deceleration in top-line growth and a massive step-back in profitability, reflecting heavy planned investments that will compress the margins management just proved they could achieve.
🐂 Bull Case
The company demonstrated immense operating leverage in Q4, delivering $8.5M in Adjusted EBITDA and generating $12.4M in Free Cash Flow for the full year. The virtual care model can be highly profitable at scale.
Omada has effectively surfed the GLP-1 wave, scaling from 50,000 to over 150,000 members on anti-obesity medications in one year. The newly announced 'GLP-1 Flex Care' provides a strategic off-ramp for employers unwilling to cover the drugs directly.
🐻 Bear Case
Core, independent revenue is stagnating. Non-related party revenue was flat sequentially in Q4 at $23.2M. The company's 58% headline growth is almost entirely manufactured by a single related party.
Despite achieving $8.5M of Adjusted EBITDA in Q4 alone, management guided the entire FY26 to just $7M-$15M. This implies the company will revert to operating near breakeven as it funds the launch of its prescribing business.
⚖️ Verdict: 🔴
Bearish. While hitting GAAP profitability is a commendable milestone, the extreme reliance on a related party for growth combined with a guided collapse in 2026 margins makes the quality of these earnings highly suspect.
Key Themes
The Related Party Growth Illusion
A granular review of the financials reveals a glaring red flag: 69% of Q4 revenue ($52.6M out of $75.8M) comes from a 'related party.' Year-over-year, this related party revenue surged 90%. Meanwhile, revenue from all other independent customers combined grew only 14% YoY and was completely flat sequentially from Q3 to Q4 ($23.2M). Management's narrative of broad-based 'multi-condition platform adoption' contradicts the reality that growth is dangerously concentrated in one captive relationship.
Aggressive GLP-1 Product Expansion
Omada is aggressively expanding its footprint in the anti-obesity market. Following the Q3 announcement of a prescribing capability, the company introduced 'GLP-1 Flex Care' in Q4. This new option allows employers to connect employees to clinical oversight and prescribing without taking on the financial burden of covering the drugs. With 150,000 members now supported on GLP-1s, this positions Omada as a central coordinator in the weight-loss ecosystem.
AI Tool Integration (OmadaSpark & Meal Map)
The integration of AI into member workflows continues to be a core driver for engagement. Tools like OmadaSpark and Meal Map are being deployed to supplement human coaches with wellness education. Management explicitly cited 'GPTs' as a primary investment pillar for 2026, aiming to improve internal productivity and member retention through real-time behavioral nudges.
2026 'Investment Year' Crushes Immediate Profitability
The Q4 print proves the model can generate high margins (11.2% Adj. EBITDA). However, the FY26 guidance indicates a reversing trend. By guiding FY26 Adjusted EBITDA to a midpoint of $11M—barely above the $8.5M generated in Q4 alone—management is signaling massive OpEx increases. The cost of launching a native prescribing service and building proprietary AI will effectively wipe out margin expansion for the next 12 months.
Expanding into New Clinical Corridors
In February 2026, the company announced 'Omada for Cholesterol,' adding to its existing diabetes, hypertension, and MSK tracks. This further entrenches the multi-condition platform strategy, increasing the surface area for cross-selling to enterprise clients who are suffering from point-solution fatigue.
Macro Impact: Evolving Drug Pricing and Medicare Policy
The broader macroeconomic environment regarding drug pricing remains a wild card. Prior calls highlighted that changes in Medicare policy or broader administration moves to lower anti-obesity medication costs (e.g., the 'TrumpRx' dynamic discussed in Q3) could act as a massive tailwind by increasing access, making Omada's navigation and prescribing tools more essential.
Other KPIs
Reversing positively from a cash burn of -$38.0 million in FY24. Operating cash flow hit $18.3M, easily covering the combined $5.8M spent on CapEx and capitalized internal-use software. The company ended the year with $222M in cash and zero long-term debt, fundamentally derisking the balance sheet.
Accelerating significantly from 69.4% in the prior year and sequential improvement from 68.2% in Q3. This metric validates the core unit economics of the digital health platform, showing that once development and fixed clinical costs are covered, incremental members fall directly to the bottom line.
Accelerating. Up 55% YoY, sequential growth from 831,000 in Q3. Member growth remains the most robust operational metric, though its quality is clouded by the heavy concentration of related party utilization.
Guidance
Decelerating. The midpoint of $317M implies 22% YoY growth. This is a dramatic slowdown from the 53% growth delivered in FY25. The deceleration suggests that the initial massive wave of GLP-1 companion growth—or the rapid expansion of the related party relationship—is beginning to plateau.
Reversing margin trajectory. While technically higher than the $6.5M achieved in FY25, it represents a massive step down from the Q4 exit velocity (where the company did $8.5M in one quarter). Implies an annual margin of just 3.5%, confirming management's prior signaling that 2026 will be a heavy investment year.
Key Questions
The Related Party Black Box
Nearly 70% of Q4 revenue came from a single related party, and core non-related revenue was flat sequentially. Can you disclose the identity of this partner, the nature of the relationship, and what specific contractual protections are in place if they decide to insource these services?
Margin Collapse Mechanics
You generated $8.5M of Adjusted EBITDA in Q4 alone, yet guide to a midpoint of $11M for all of FY26. Exactly how much capital is being allocated to the new prescribing and AI initiatives, and what is the expected payback period for these investments?
Growth Deceleration Drivers
Revenue growth is projected to slow from 58% in Q4 to 22% for FY26. Is this deceleration primarily a function of lapping large initial enterprise rollouts, a slowdown in the related party's expansion, or conservative forecasting around the new prescribing launch?